American Journal of Respiratory and Critical Care Medicine Vol 165. pp. 1581-1586, (2002)
© 2002 American Thoracic Society
Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome
Demosthenes Bouros,
Athol U. Wells,
Andrew G. Nicholson,
Thomas V. Colby,
Vlasis Polychronopoulos,
Panos Pantelidis,
Patricia L. Haslam,
Dimitris A. Vassilakis,
Carol M. Black and
Roland M. du Bois
Royal Brompton Hospital; Royal Free Hospital, London, United Kingdom; and Mayo Clinic, Scottsdale, Arizona
Correspondence and requests for reprints should be addressed to Athol Wells, M.D., Interstitial Lung Disease Unit, National Heart and Lung Institute, at Imperial College, Emmanuel Kaye Bld, 1 Manresa Rd., London SW3 6LR, UK. E-mail: a.wells{at}rbh.nthames.nhs.uk
Fibrosing alveolitis associated with systemic sclerosis (FASSc) has a better prognosis than idiopathic pulmonary fibrosis. In view of recent reports that idiopathic nonspecific interstitial pneumonia (NSIP) has a better prognosis than idiopathic usual interstitial pneumonia (UIP), we classified histologic appearances of surgical lung biopsies performed in 80 patients with FASSc. NSIP (n = 62, 77.5%), subcategorized as cellular NSIP (n = 15) and fibrotic NSIP (n = 47) was much more prevalent than UIP (n = 6), end-stage lung disease (ESL, n = 6), or other patterns (n = 6). There were 25 deaths (NSIP 16/62, 26%; UIP/ESL 6/12, 50%). Five-year survival differed little between NSIP (91%) and UIP/ESL (82%); mortality was associated with lower initial carbon monoxide diffusing capacity (DLCO) and FVC levels (p = 0.004 and p = 0.007, respectively). Survival and serial FVC and DLCO trends did not differ between cellular and fibrotic NSIP. Increased mortality in NSIP was associated with lower initial DLCO levels (p = 0.04), higher BAL eosinophil levels (p = 0.03), and deterioration in DLCO levels during the next 3 years (p < 0.005). We conclude that NSIP is the histopathologic pattern in most patients with FASSc. However, outcome is linked more strongly to disease severity at presentation and serial DLCO trends than to histopathologic findings.
Key Words: fibrosing alveolitis systemic sclerosis nonspecific interstitial pneumonia histopathology survival
This article has been cited by other articles:

|
 |

|
 |
 
K. M. Antoniou, D. M. Hansell, M. B. Rubens, K. Marten, S. R. Desai, N. M. Siafakas, A. G. Nicholson, R. M. du Bois, and A. U. Wells
Idiopathic Pulmonary Fibrosis: Outcome in Relation to Smoking Status
Am. J. Respir. Crit. Care Med.,
January 15, 2008;
177(2):
190 - 194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. E. Tzelepis, S. P. Toya, and H. M. Moutsopoulos
Occult connective tissue diseases mimicking idiopathic interstitial pneumonias
Eur. Respir. J.,
January 1, 2008;
31(1):
11 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Strange, M. B. Bolster, M. D. Roth, R. M. Silver, A. Theodore, J. Goldin, P. Clements, J. Chung, R. M. Elashoff, R. Suh, et al.
Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease
Am. J. Respir. Crit. Care Med.,
January 1, 2008;
177(1):
91 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. du Bois and T. E King Jr
Challenges in pulmonary fibrosis {middle dot} 5: The NSIP/UIP debate
Thorax,
November 1, 2007;
62(11):
1008 - 1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Kim and S. Nagai
Idiopathic Nonspecific Interstitial Pneumonia: An Unrecognized Autoimmune Disease?
Am. J. Respir. Crit. Care Med.,
October 1, 2007;
176(7):
632 - 633.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Kinder, H. R. Collard, L. Koth, D. I. Daikh, P. J. Wolters, B. Elicker, K. D. Jones, and T. E. King Jr.
Idiopathic Nonspecific Interstitial Pneumonia: Lung Manifestation of Undifferentiated Connective Tissue Disease?
Am. J. Respir. Crit. Care Med.,
October 1, 2007;
176(7):
691 - 697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. BEREZNE, D. VALEYRE, B. RANQUE, L. GUILLEVIN, and L. MOUTHON
Interstitial Lung Disease Associated with Systemic Sclerosis: What Is the Evidence for Efficacy of Cyclophosphamide?
Ann. N.Y. Acad. Sci.,
September 1, 2007;
1110(1):
271 - 284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. du Bois
State of the Art. Mechanisms of Scleroderma-induced Lung Disease
Proceedings of the ATS,
August 15, 2007;
4(5):
434 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Penn, A.J. Howie, E.J. Kingdon, C.C. Bunn, R.J. Stratton, C.M. Black, A. Burns, and C.P. Denton
Scleroderma renal crisis: patient characteristics and long-term outcomes
QJM,
August 1, 2007;
100(8):
485 - 494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Tiev, J. Cabane, F. Aubourg, A. Kettaneh, M. Ziani, L. Mouthon, S. Duong-Quy, I. Fajac, L. Guillevin, and A. T. Dinh-Xuan
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
Eur. Respir. J.,
July 1, 2007;
30(1):
26 - 30.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Park, D. S. Kim, I-N. Park, S. J. Jang, M. Kitaichi, A. G. Nicholson, and T. V. Colby
Prognosis of Fibrotic Interstitial Pneumonia: Idiopathic versus Collagen Vascular Disease-related Subtypes
Am. J. Respir. Crit. Care Med.,
April 1, 2007;
175(7):
705 - 711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Scheja, K. Larsen, L. Todorova, E. Tufvesson, M. Wildt, A. Akesson, L. Hansson, S. Ellis, and G. Westergren Thorsson
BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis
Eur. Respir. J.,
March 1, 2007;
29(3):
446 - 452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M H Buch, C P Denton, D E Furst, L Guillevin, L J Rubin, A U Wells, M Matucci-Cerinic, G Riemekasten, P Emery, H Chadha-Boreham, et al.
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
Ann Rheum Dis,
February 1, 2007;
66(2):
169 - 173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Cottin
Interstitial lung disease: are we missing formes frustes of connective tissue disease?
Eur. Respir. J.,
November 1, 2006;
28(5):
893 - 896.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. C. Liossis, A. Bounas, and A. P. Andonopoulos
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
Rheumatology,
August 1, 2006;
45(8):
1005 - 1008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez and W. J. McCune
Cyclophosphamide for scleroderma lung disease.
N. Engl. J. Med.,
June 22, 2006;
354(25):
2707 - 2709.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Rigamonti, L M Shand, M Feudjo, C C Bunn, C M Black, C P Denton, and A K Burroughs
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis
Gut,
March 1, 2006;
55(3):
388 - 394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez
Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia.
Proceedings of the ATS,
January 1, 2006;
3(1):
81 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. B.S. Prakash
Uncommon Causes of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Chest,
January 1, 2006;
129(1_suppl):
206S - 219S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. W. Noble, L. Tanoue, and R. Homer
Case Study Review
Chest,
November 1, 2005;
128(5_suppl_1):
540S - 546S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. King Jr.
Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases
Am. J. Respir. Crit. Care Med.,
August 1, 2005;
172(3):
268 - 279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-K. Lee, D. S. Kim, B. Yoo, J. B. Seo, J.-Y. Rho, T. V. Colby, and M. Kitaichi
Histopathologic Pattern and Clinical Features of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Chest,
June 1, 2005;
127(6):
2019 - 2027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Grutters and R. M. du Bois
Genetics of fibrosing lung diseases
Eur. Respir. J.,
May 1, 2005;
25(5):
915 - 927.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Ito, S. Nagai, M. Kitaichi, A. G. Nicholson, T. Johkoh, S. Noma, D. S. Kim, T. Handa, T. Izumi, and M. Mishima
Pulmonary Manifestations of Primary Sjogren's Syndrome: A Clinical, Radiologic, and Pathologic Study
Am. J. Respir. Crit. Care Med.,
March 15, 2005;
171(6):
632 - 638.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Desai, S. Veeraraghavan, D. M. Hansell, A. Nikolakopolou, N. S. L. Goh, A. G. Nicholson, T. V. Colby, C. P. Denton, C. M. Black, R. M. du Bois, et al.
CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia
Radiology,
August 1, 2004;
232(2):
560 - 567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F Meloni, R Caporali, A Marone Bianco, E Paschetto, M Morosini, A M Fietta, F Bobbio-Pallavicini, E Pozzi, and C Montecucco
Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia
Ann Rheum Dis,
July 1, 2004;
63(7):
892 - 894.
[Full Text]
|
 |
|

|
 |

|
 |
 
A G Nicholson, B J Addis, H Bharucha, C A Clelland, B Corrin, A R Gibbs, P S Hasleton, K M Kerr, N B N Ibrahim, S Stewart, et al.
Inter-observer variation between pathologists in diffuse parenchymal lung disease
Thorax,
June 1, 2004;
59(6):
500 - 505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasse, K-M. Muller, C. Kurz, H. Hamm, and J.C. Virchow Jr
Does interferon-{gamma} improve pulmonary function in idiopathic pulmonary fibrosis?
Eur. Respir. J.,
December 1, 2003;
22(6):
906 - 911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. W. Noble and D. G. Morris
Time Will Tell: Predicting Survival in Idiopathic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med.,
September 1, 2003;
168(5):
510 - 511.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Ross
The Clinical Diagnosis of Asbestosis in This Century Requires More Than a Chest Radiograph
Chest,
September 1, 2003;
124(3):
1120 - 1128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. I. Latsi, R. M. du Bois, A. G. Nicholson, T. V. Colby, D. Bisirtzoglou, A. Nikolakopoulou, S. Veeraraghavan, D. M. Hansell, and A. U. Wells
Fibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Am. J. Respir. Crit. Care Med.,
September 1, 2003;
168(5):
531 - 537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Cottin, F. Thivolet-Bejui, M. Reynaud-Gaubert, J. Cadranel, P. Delaval, P-J. Ternamian, J-F. Cordier, and and the Groupe d'Etudes et de Recherche sur les Ma
Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis
Eur. Respir. J.,
August 1, 2003;
22(2):
245 - 250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Flaherty, T. V. Colby, W. D. Travis, G. B. Toews, J. Mumford, S. Murray, V. J. Thannickal, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al.
Fibroblastic Foci in Usual Interstitial Pneumonia: Idiopathic versus Collagen Vascular Disease
Am. J. Respir. Crit. Care Med.,
May 15, 2003;
167(10):
1410 - 1415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Saravanan and C. A. Kelly
Survival in fibrosing alveolitis associated with rheumatoid arthritis is better than cryptogenic fibrosing alveolitis
Rheumatology,
April 1, 2003;
42(4):
603 - 604.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, and Journalology in AJRCCM 2002
Am. J. Respir. Crit. Care Med.,
February 1, 2003;
167(3):
345 - 355.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Renzoni, D. A. Walsh, M. Salmon, A. U. Wells, P. Sestini, A. G. Nicholson, S. Veeraraghavan, A. E. Bishop, H. M. Romanska, P. Pantelidis, et al.
Interstitial Vascularity in Fibrosing Alveolitis
Am. J. Respir. Crit. Care Med.,
February 1, 2003;
167(3):
438 - 443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. King Jr.
Nonspecific Interstitial Pneumonia and Systemic Sclerosis
Am. J. Respir. Crit. Care Med.,
June 15, 2002;
165(12):
1578 - 1579.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 American Thoracic Society
|
|
|